At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Rituximabdrug
Likely dose
Rituximab 1000mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PhaseI/II Prospective, Randomized, Dose-Ranging Pilot Study of Rituximab in the Treatment of Refractory Scleritis and Non-Infectious Orbital Inflammation
In Brief
A Phase 2 clinical trial evaluating Rituximab for Scleritis and Orbital Disease. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the safety and tolerability of Rituximab in refractory scleritis and non-infectious orbital inflammation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScleritis, Orbital Disease
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2006
Enrollment StartJan 2007
Primary CompletionMar 2011
TodayJul 2026
First PostedDec 25, 2006
Enrollment StartJan 1, 2007
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 19.5 years ago
Interventions
Rituximabdrug
Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.